Drug-sensitivity testing in patients with human oesophageal squamous cell carcinoma.
To evaluate the response to chemotherapeutic agents against human oesophageal cancer, 19 samples were tested by the human tumour clonogenic assay (HTCA), 21 samples by subrenal capsule assay (SRCA) and 33 samples by SRCA with immunosuppressant (IS-SRCA). The evaluability rate of was 21% for HTCA, 95% for SRCA and 91% for IS-SRCA. No active agent was detected by HTCA, however, 29% of the drugs tested by SRCA and 22% by IS-SRCA were considered to be active. Histological analysis revealed substantial inflammatory infiltrates and poor tumour cell preservation with SRCA; however, infiltrates were minimal and there was a high degree of tumour cell preservation with IS-SRCA. The response rates of IS-SRCA were comparable with those of prior clinical tests for each drug. These results suggested that IS-SRCA is the most useful drug sensitivity test for human oesophageal cancer.
Terashima
M
M
First Department of Surgery, School of Medicine, Iwate Medical University, Japan.
Ikeda
K
K
Maesawa
C
C
Kawamura
H
H
Ishida
K
K
Sato
M
M
Saito
K
K
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D005069:Evaluation Studies as Topic; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D051379:Mice; D008815:Mice, Inbred Strains; D013370:Subrenal Capsule Assay / Q000379:methods; D014410:Tumor Stem Cell Assay / Q000379:methods
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents